Context Therapeutics Q3 net loss narrows as R&D costs fall

Overview

• US biopharma firm's Q3 net loss narrowed from prior year

• Research and development expenses fell, mainly due to lower CT-202 costs

• Cash and cash equivalents expected to fund operations into early Q4 2027

Outlook

• Company expects cash to fund operations to early Q4 2027

• Context plans to initiate Phase 1b CTIM-76 trial in Q1 2027

• Company expects initial CTIM-76 Q3W efficacy data in Q2 2027

Result Drivers

• R&D EXPENSES - Q3 research and development expenses declined mainly due to lower CT-202 contract manufacturing and preclinical costs

• PERSONNEL COSTS - Higher salaries and share-based compensation drove increased general and administrative expenses

• INTEREST INCOME - Lower interest income contributed to reduced other income in Q3

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Context Therapeutics Inc is $5.00, about 2,396.3% above its November 9 closing price of $0.20

Reuters Recommended Reads

• Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

• Nov 10 - Coya Therapeutics Q3 R&D expenses more than double due to trial advancement

• Nov 9 - Perspective Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)